摘要
目的:探讨经皮冠状动脉介入治疗(PCI)对急性冠脉综合征(ACS)术后48 h B型尿钠肽(PRO-BNP)水平的影响及其预测近、远期心血管事件的临床意义。方法:将2007年1月～2010年1月我院收治的80例ACS患者随机分为对照组和观察组,每组各40例,分别在术前和术后给予常规治疗和在常规治疗的同时行规范化PCI术,对术后48 h的PRO-BNP水平进行检测,同时观察术后3、6个月的心血管事件发生率,评价其与PRO-BNP水平的关联性。结果:术后48 h,PRO-BNP出现不同程度的下降,但观察组下降程度显著高于对照组,差异有统计学意义(P<0.05)。其中,PRO-BNP浓度<800 pg/ml的患者比例及PRO-BNP水平显著优于PRO-BNP浓度>800 pg/ml患者的相应指标,差异均有统计学意义(均P<0.05);术后3个月,PRO-BNP<800 pg/ml与PRO-BNP>800 pg/ml心血管事件发生率比较,差异有高度统计学意义(P<0.01);术后6个月,二者比较,差异无统计学意义(P>0.05)。结论:PCI对于ACS的治疗效果确切、显著,可有效降低血浆PRO-BNP水平,PRO-BNP水平对于术后短期心血管事件具有预测价值,对于远期的预测价值不明显。
Objective： To discuss the influence of the PCI to the level of 48 h PRO-BNP of the post-operation of ACS and to predict the clinical significance of short term and long term cardiovascular cases. Methods： The conventional therapy and standardized PCI during pre-operation and post-operation were given to 80 ACS patients from January 2007 to January 2010. The patients were divided into observation group（40 cases） and control group（40 cases）. The PRO-BNP level in 48 h after the operation was checked. Meanwhile, the cardiovascular diseases rate in 3, 6 months after the operation and its relevance to the PRO-BNP level were observed. Results： After 48 h, the level of PRO-BNP fell in different degree, there was a significant difference in the observation group and control group （P〈0.05）. The patient rate and its PRO-BNP level （〈800 pg/ml） were dramatically better than those of the patient rate and its PRO-BNP level （〉800 pg/ml） （P〈0.05）. After 3 months, the cardiovascular diseases rate in PRO-BNP〈800 pg/ml was obviously lower than PRO-BNP〉800 pg/ml （P〈 0.05）, while after 6 months, the rate was not obvious （P〉0.05）. Conclusion： The effect of PIC to ACS is accurate, significant, it can reduce the plasma＇s PRO-BNP level effectively. The PRO-BNP level has the predictive value to the short term cardiovascular cases after operation, which does little to the long term cardiovascular cases.
出处
《中国医药导报》
CAS
2011年第26期53-54,57,共3页
China Medical Herald
关键词
急性冠脉综合征
B型尿钠肽
介入治疗
Acute coronary syndrome
B type natriuretic peptide
Interventional therapy
